Physician profile
Birjitender Singh
NPI 1124131719
$5,486.72
in general payments reported to CMS, 2019-2025
37 companies · $2,615 in 2025
The $2,615 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $511 · 2021: $284 · 2022: $309 · 2023: $654 · 2024: $492 · 2025: $2,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Travel and Lodging: $1,760 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.56 |
| Travel and Lodging | $1,759.75 |
| Education | $103.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,305.70 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $367.61 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Indivior INC. | $261.16 | 2019-2025 | Sublocade |
| Shockwave Medical, INC | $246.67 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $238.61 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $195.83 | 2019-2021 | |
| Orexo US, INC. | $171.66 | 2019-2025 | Zubsolv |
| Janssen Pharmaceuticals, INC | $170.62 | 2019 | |
| Abbvie INC. | $156.27 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $114.66 | 2019-2023 | Emgality, Jardiance |
| Eisai INC. | $109.92 | 2020-2021 | |
| Alkermes, INC. | $103.95 | 2025 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $102.04 | 2019-2023 | |
| Amarin Pharma, INC. | $98.48 | 2020-2022 | |
| Abbott Laboratories | $79.94 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $76.54 | 2019-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $59.50 | 2019-2020 | |
| Scpharmaceuticals INC. | $59.44 | 2024 | |
| Allergan, INC. | $57.80 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $54.66 | 2023 | Seglentis, Livalo |
| Axsome Therapeutics, INC. | $50.21 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $48.90 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $42.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.61 | 2019-2023 | Jardiance |
| Medtronic Minimed, INC. | $32.99 | 2019 | |
| Grt US Holding, INC. | $30.17 | 2022 | |
| Dexcom, INC. | $28.15 | 2021 | |
| Exact Sciences Corporation | $27.30 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $21.11 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $20.69 | 2020 | |
| Smith+Nephew, INC. | $20.08 | 2023 | Grafix Pl |
| Phathom Pharmaceuticals, INC. | $17.50 | 2024 | Voquezna |
| Bioventus LLC | $17.12 | 2025 | Durolane |
| Circassia INC. | $16.83 | 2019 | |
| Boston Scientific Corporation | $15.29 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2022 | |
| Amgen INC. | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birjitender Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.